Clearside Biomedical, Inc. (NASDAQ:CLSD) Files An 8-K Results of Operations and Financial Condition

Clearside Biomedical, Inc. (NASDAQ:CLSD) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

On March 14, 2018, Clearside Biomedical, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2017, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit

Number

ExhibitDescription

99.1

Press Release, dated March 14, 2018


Clearside Biomedical, Inc. Exhibit
EX-99.1 2 clsd-ex991_6.htm EX-99.1 clsd-ex991_6.htm Exhibit 99.1     Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update   ALPHARETTA,…
To view the full exhibit click here

About Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

An ad to help with our costs